

LISTING OF THE CLAIMS

1. (Cancelled).
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (Cancelled).
9. (Cancelled).
10. (Cancelled).
11. (Cancelled).
12. (Cancelled).
13. (Cancelled).
14. (Cancelled).
15. (Cancelled).
16. (Cancelled).
17. (Cancelled).

18. (Cancelled).

19. (Cancelled).

20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Currently Amended). A pharmaceutical composition comprising:
fenofibric acid or a calcium or quaternary ammonium salt thereof; and
at least one binder,
wherein the fenofibric acid content comprises 5 to 60% by weight of the composition.

24. (Previously Presented). The pharmaceutical composition of claim 23, wherein the composition further comprises a coating.

25. (Previously Presented). The pharmaceutical composition of claim 23, wherein the binder is an enteric binder.

26. (Previously Presented). The pharmaceutical composition of claim 25, wherein the enteric binder is an enteric polymer.

27. (Previously Presented). The pharmaceutical composition of claim 26, wherein the enteric polymer is selected from the group consisting of hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethylcellulose sodium.

28. (Previously Presented). The pharmaceutical composition of claim 27, wherein the enteric polymer is selected from copolymers based on (meth)acrylic acid and at least one alkyl (meth)acrylic acid ester.

29. (Previously Presented). The pharmaceutical composition of claim 28, wherein the alkyl (meth)acrylic acid ester is methyl methacrylate.

30. (Previously Presented). The pharmaceutical composition of claim 29, wherein the copolymers have a ratio of free carboxyl groups to esterified carboxyl groups of 2:1 to 1:3.

31. (Previously Presented). The pharmaceutical composition of claim 30, wherein the ratio is 1:1.

32. (Deleted).

33. (Previously Presented). The pharmaceutical composition of claim 23, wherein the binder is a non-enteric binder.

34. (Previously Presented). The pharmaceutical composition of claim 33, wherein the non-enteric binder is selected from the group consisting of: a synthetic polymer, a modified natural polymer, a natural polymer and a nonpolymeric binder.

35. (Previously Presented). The pharmaceutical composition of claim 23, wherein the composition is a tablet.

36. (Previously Presented). The pharmaceutical composition of claim 23, wherein the composition is a capsule.

37. (Previously Amended). A method for oral administration of fenofibric acid or a calcium or quaternary ammonium salt thereof, comprising administering the pharmaceutical composition of claim 23.

38 (Previously Presented). The pharmaceutical composition of claim 24, wherein the coating is an enteric coating.